I specialize in the care of patients with Hodgkin and non-Hodgkin lymphoma. I am Clinical Director of the Division of Hematologic Oncology and I am board-certified in internal medicine, medical oncology, and hematology. Recognizing that advances in medicine come about as a result of clinical research, I am the Principal Investigator for a number of clinical trials aimed at improving the care of patients with lymphoma. The findings of several of the clinical trials I have led have changed the international standard of care.
My research has focused on improving the outcome of patients with poor-risk diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma (HL). This effort has been conducted along two tracks. One effort is focused on improving therapy for patients with disease that has returned or is not responding to standard therapy (refractory disease), through the use of high-dose therapy and autologous stem cell transplantation as well as new agents that can be incorporated into such “salvage” therapy.
A second approach involves developing strategies to optimize the treatment of newly diagnosed DLBCL according to the likelihood of their disease recurring (“risk-adapted therapy”), using what we have learned by studying patients with relapsed or refractory disease. We design risk-adapted therapy according to a patient's risk factors before treatment (clinical, molecular, or pathologic features of the disease) and the results of imaging studies.